Businesswoman with Mask

05.07.2021

A recent paper written by economist Martin Ellison of Oxford University. biologist David Sinclair of Harvard Medical School, and economist Andrew Scott from London Business School, calculates that an intervention that successfully slows down biological aging—lowering mortality and frailty at each age, such that U.S. life expectancy would increase by just one year—is estimated to be worth $37 trillion in net present value terms. That’s the equivalent of around $700 billion annually, more than 3 percent of the country’s entire GDP.

A recent paper written by economist Martin Ellison of Oxford University. biologist David Sinclair of Harvard Medical School, and economist Andrew Scott from London Business School, calculates that an intervention that successfully slows down biological aging—lowering mortality and frailty at each age, such that U.S. life expectancy would increase by just one year—is estimated to be worth $37 trillion in net present value terms. That’s the equivalent of around $700 billion annually, more than 3 percent of the country’s entire GDP.

The economic value of targeting aging